Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
XORTX Therapeutics Inc ( (TSE:XRTX) ) has provided an update.
On March 5, 2026, XORTX Therapeutics Inc. announced it had filed and mailed its notice of meeting, management information circular and related materials for its upcoming Annual and Special Meeting of shareholders. The documents are available on the company’s website, Canadian securities regulator platform SEDAR+ and the U.S. SEC site, with mailing of the circular and supporting materials having occurred on March 2, 2026.
The shareholder meeting is scheduled for March 24, 2026, at the company’s Calgary offices, where investors will vote on director elections, auditor appointment and remuneration, confirmation of the stock option plan and a proposed share consolidation of up to five pre-consolidation shares for one post-consolidation share. The board unanimously recommends voting for all resolutions, and shareholders of record as of February 20, 2026, are urged to submit their proxies by the March 20, 2026 deadline using online, telephone or other available voting methods.
The most recent analyst rating on (TSE:XRTX) stock is a Sell with a C$0.46 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.
Spark’s Take on TSE:XRTX Stock
According to Spark, TipRanks’ AI Analyst, TSE:XRTX is a Neutral.
The score is driven primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn despite some improvement) and bearish technicals (below key moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend.
To see Spark’s full report on TSE:XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies for gout and progressive kidney diseases. Its pipeline includes three clinically advanced programs—XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease and XRx-101 for acute kidney and organ injury linked to respiratory virus infections—plus a preclinical program, XRx-225, targeting Type 2 diabetic nephropathy and aberrant purine metabolism.
Average Trading Volume: 7,969
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$3.48M
Learn more about XRTX stock on TipRanks’ Stock Analysis page.